|
Market Closed -
Nasdaq
02:30:00 14/11/2026 am IST
|
5-day change | 1st Jan Change | ||
| 0.4130 USD | -6.16% |
|
-5.36% | -73.86% |
| 12/10 | Certain Common Stock of Outlook Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 12-OCT-2026. | CI |
| 09/10 | Outlook Therapeutics Names Greg DiPasquale Chief Commercial Officer | MT |
Company Valuation: Outlook Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: September | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 380.5 | 275.9 | 57.51 | 126.3 | 47.08 | 100.5 | - | - |
| Change | - | -27.49% | -79.15% | 119.63% | -62.73% | 113.54% | - | - |
| Enterprise Value (EV) | 380.5 | 275.9 | 57.51 | 126.3 | 47.08 | 100.5 | 100.5 | 100.5 |
| Change | - | -27.49% | -79.15% | 119.63% | -62.73% | 113.54% | 0% | 0% |
| P/E | -6.2x | -3.94x | -0.92x | -1.32x | -0.59x | -0.71x | -1.91x | 4.59x |
| PBR | 71.9x | 29.6x | - | - | - | - | - | - |
| PEG | - | 0.3x | 0x | 0.1x | 0x | 0x | 0x | -0x |
| Capitalization / Revenue | - | - | - | - | 33.3x | 147x | 2.28x | 0.59x |
| EV / Revenue | - | - | - | - | 0x | 147x | 2.28x | 0.59x |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| EV / EBIT | -0x | -0x | -0x | -0x | -0x | -1.89x | -2.94x | 1.26x |
| EV / FCF | - | -0x | -0x | - | - | -2.58x | -9.14x | 0.74x |
| FCF Yield | - | -20.5% | -74.7% | - | - | -38.8% | -10.9% | 134% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -7 | -6.2 | -4.8 | -4.06 | -1.79 | -0.58 | -0.2167 | 0.09 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | - | - | - | - | 1.413 | 0.6827 | 44.07 | 170.7 |
| EBITDA | - | - | - | - | - | - | - | - |
| EBIT 1 | -51.73 | -63.07 | -53.13 | -71.7 | -67.06 | -53.11 | -34.16 | 80.01 |
| Net income 1 | -53.16 | -66.05 | -58.98 | -75.37 | -62.42 | -65.1 | -44.43 | 20.8 |
| Net Debt | - | - | - | - | - | - | - | - |
| Reference price 2 | 43.4000 | 24.4000 | 4.4200 | 5.3400 | 1.0600 | 0.4130 | 0.4130 | 0.4130 |
| Nbr of stocks (in thousands) | 8,767 | 11,307 | 13,012 | 23,656 | 44,420 | 2,43,448 | - | - |
| Announcement Date | 22/12/21 | 29/12/22 | 22/12/23 | 27/12/24 | 19/12/25 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
| -0.71x | - | - | - | 10Cr | ||
| 17.35x | 6.64x | 12.72x | 1.72% | 6.63TCr | ||
| 32.78x | 8.77x | 28.98x | 0.07% | 6.06TCr | ||
| 38.6x | 6.87x | 20.53x | 0.84% | 5.55TCr | ||
| 44.7x | 6.25x | 29.77x | -.--% | 4.76TCr | ||
| 34.6x | 3.29x | 14.2x | -.--% | 4.37TCr | ||
| -20.57x | 54.42x | -22.49x | -.--% | 3.73TCr | ||
| 36.15x | 8.94x | 23.31x | 0.36% | 3.66TCr | ||
| 40.59x | 7.91x | 26.38x | -.--% | 3.22TCr | ||
| -73.93x | 14x | -75.29x | -.--% | 2.66TCr | ||
| Average | 14.96x | 13.01x | 6.46x | 0.33% | 4TCr | |
| Weighted average by Cap. | 21.69x | 11.75x | 11.42x | 0.44% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- OTLK Stock
- Valuation Outlook Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
















